Positive Outlook for Valneva Driven by Promising Vaccine Developments and Market Opportunities

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Valneva (VALN – Research Report), with a price target of $17.00.

Edward White’s rating is based on several promising developments for Valneva. The company is co-developing a Lyme disease vaccine, VLA15, with Pfizer, which is currently in Phase 3 trials. The trial is evaluating the vaccine’s efficacy, safety, and immunogenicity, with a data readout expected by the end of 2025. If successful, Pfizer plans to submit regulatory applications in 2026, with a potential market launch in 2027 and significant sales growth anticipated by 2029.
Additionally, Valneva’s chikungunya vaccine, Ixchiq, has exceeded sales expectations and received accelerated approval from the FDA. The vaccine is also approved in several other regions and has recently had its label extended in the EU to include younger age groups. These factors, combined with the potential market opportunities for both vaccines, contribute to a positive outlook for Valneva’s stock.